CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Status:
Completed
Trial end date:
2021-03-20
Target enrollment:
Participant gender:
Summary
The purpose this research study is to determine if the combination of nivolumab and CMP-001
improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic
response rate).